|
Affordable medicine is a grand challenge of our time.
OSP3 was a singular gathering of researchers, entrepreneurs, industry professionals, funders and NGOs and who want to achieve radical improvements in the way therapeutics are delivered to market in the 21st century. Open source brings the promise of efficient, robust and inclusive routes to discovery. While great progress has been made in opening up the discovery and development of new medicines, there remain major barriers to open source medicines reaching patients. Our task in this meeting was to learn about and spark new initiatives, to understand the main challenges together and to propose new, realistic solutions for implementation. This meeting followed the 1st OSP conference, which took place at the Bellagio Center, Lake Como, Italy in 2014, and the second, which took place at Castle Rauischholzhausen, Marburg, Germany in 2015. Partners and sponsors have included The Rockefeller Foundation, Open Society Foundations and Tata Trusts. The OSP3 meeting was sponsored by CRI Research, with support from DRUID - Giessen University.
|
|
World TB Day
|
Partners and Sponsors: CRI-Paris, Cures Within Reach, DRUID, European & Developing Countries Clinical Trials Partnership, Harvard Global Health Institute, Mayo Clinic TB Center, Open Source Malaria, Open Source Pharma Foundation, Philipps-University Marburg, Sage Bionetworks, Tata Trusts
Venue: The newly renovated building of CRI, a global leader in open science and quantitative approaches to biology, situated in the heart of Paris. Organizing Contacts: Wengsi Chiu (Open Source Pharma, weng-si.chiu@mail.mcgill.ca) Victoria Diez (CRI, victoria.diez@cri-paris.org) Alina Grenier-Arellano (Open Source Pharma, alina.grenierarellano@mail.mcgill.ca) Peter Kolb (University of Marburg, peter.kolb@uni-marburg.de) Ariel Lindner (CRI, ariel.lindner@inserm.fr) Jaykumar Menon (Harvard University, jmenon@hsph.harvard.edu) Matthew Todd (University College London, matthew.todd@ucl.ac.uk) |
Previous Conferences:
|
Number of Attendees: small (~50) select group of the world's thought leaders, feeding significant “live” social media outreach
Participants:
Participants:
- Eric Anderson (Artist in Residence, Open Source Pharma Foundation, Rochester)
- Urmi Bajpai (University of Delhi, Delhi)
- Mostapha Benhenda (Founder, Startcrowd, San Francisco)
- Bryn Bellomy (Conscience Inc., New York)
- Anshu Bhardwaj (Center for Research and Interdisciplinarity, Paris)
- Marc Bianciotto (Sanofi, Paris)
- Anneke Blackburn (Australian National University, Canberra)
- Bruce Bloom (CEO, Cures Within Reach, Chicago)
- Samir Brahmachari (Founder, Open Source Drug Discovery; AcSIR, Delhi)
- Nadine Bongaerts (Center for Research and Interdisciplinarity, Paris)
- Tanusree Chaudhuri (Open Source Pharma Foundation, Bangalore)
- Karmen Condic-Jurkic (Open Force Field Consortium, Zagreb)
- Julia Daniel (Stanford University, Stanford)
- Anjana Dhar Koul (Janssen, Beerse)
- Keith Elliston (i2b2/tranSMART; Open Source Pharma Foundation, Boston)
- Stephen Friend (Chair, Sage Bionetworks; ex senior VP, Merck, Seattle)
- Nicole Foti (Open Insulin Project, San Francisco)
- Bareket Gelbhart (Gelbhart Innovations, Lugano)
- Lee Hartwell (Nobel Laureate; Arizona State University, Arizona) (by video)
- Melanie Heard (Center for Research and Interdisciplinarity, Paris)
- Martin Hetu (HEC, Paris)
- UCA Jaleel (Principal Scientist, Open Source Pharma Foundation, Bangalore)
- Linda Kahl (Senior Counsel & Director of Ownership and Innovation, BioBricks, San Francisco)
- Paul Kohlhaas (Molecule, Basel)
- Peter Kolb (Philipps University-Marburg, Marburg)
- Thomas Landrain (Just One Giant Lab, Paris)
- Ariel Lindner (Co-founder, Center for Research and Interdisciplinarity, Paris)
- Amanda McPherson (Linux Foundation, San Francisco)
- Jaykumar Menon (Harvard University, Boston; Open Source Pharma Foundation, Bangalore)
- Alice Motion (University of Sydney, Sydney)
- Bernard Munos (FasterCures; Forbes; ex-Eli Lilly, Indiana)
- Niclas Nilsson (LEO Pharma, Ballerup)
- Ole Oleson (European & Developing Countries Clinical Trials Partnership, Amsterdam)
- Ochoro Otunnu (Founder, Africa Aids Initiative, Africa Center for Democracy, New York)
- Benjamin Perry (Senior Discovery Manager, Drugs for Neglected Diseases Initiative, Geneva)
- Nibedita Rath (Scientific Director, Open Source Pharma Foundation, Bangalore)
- Guy Rouleau (Director, Montreal Neurological Institute and Hospital, McGill University, Montreal)
- Tomasz Sablinski (CEO, Transparency Life Sciences, New York) (by video)
- William Scott (Professor, IUPUI - Indiana University-Purdue University Indianapolis, Indiana)
- Anne-Marie Shand (Taylor & Francis, Oxford)
- Sitta Sittampalam (Senior Advisor, National Center for Advancing Translational Sciences, Maryland)
- Geoffrey Siwo (University of Notre Dame, Indiana)
- Ellen 't Hoen (Medicines Law & Policy, Amsterdam)
- Zelalem Temesgen (Head, Mayo Clinic Center for Tuberculosis, Minnesota)
- Matthew Todd (University College London; Founder, Open Source Malaria, London)
- Andy Updegrove (Gesmer Updegrove LLP, Boston)
- John Wilbanks (Sage Bionetworks, Seattle)
- Jake Wintermute (Center for Research and Interdisciplinarity, Paris)